WCLC 2022 | The DLL3-targeting BiTE, tarlatamab, for the treatment of SCLC

Delta-like ligand 3 (DLL3) is overexpressed in the majority of small cell lung cancer (SCLC). Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, provides an overview of a Phase I dose exploration study (NCT03319940) investigating tarlatamab, a half-life extended bispecific T cell engager (BiTE) which binds to DLL3 and CD3, thereby inducing T-cell mediated tumor lysis. Tarlatamab demonstrated a manageable safety profile and encouraging efficacy in a heavily pretreated SCLC population. Prof. Borghaei emphasizes the need for additional studies to identify the optimal approach to use tarlatamab in this difficult-to-treat patient population. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.